Intrabursal Administration of Clodronate Liposomes

Posted by Catalina Garcia on May 20th, 2024

The use of liposomes as drug delivery systems has revolutionized the field of medicine. One such application is the intrabursal administration of clodronate liposomes, a method that has gained recognition for its efficacy in the treatment of various reproductive disorders.

Mechanism of Action for Intrabursal Administration of Clodronate Liposomes

The mechanism of action for intrabursal administration of clodronate liposomes involves the targeted depletion of macrophages. Clodronate is encapsulated within liposomes, small lipid vesicles that can contain hydrophobic drugs. When administered intrabursally, these liposomes are taken up by resident macrophages.

Once inside the macrophages, clodronate inhibits farnesyl pyrophosphate synthase, a vital enzyme involved in the mevalonate pathway. This pathway is essential for producing isoprenoids, which are crucial for the function and survival of macrophages. By disrupting this pathway, clodronate induces apoptosis, resulting in the elimination of macrophages in the bursal sac.